Document:

GenoMed, Inc. Exhibit 10.22

                             STOCK OPTION AGREEMENT

THIS AGREEMENT is made effective as of February 22, 2003, between GenoMed, Inc.
a Florida corporation ("Company") and the undersigned ("Director").

WHEREAS, the undersigned has been appointed to serve a one year term as a
Director of the Company, which has an active trading market for its common stock
("Common Stock");

WHEREAS, the Company desires to compensate Directors for past and future
services to the Company by affording the Director an opportunity to purchase
shares of its Common Stock par value $0.0001 (the "Shares"), pursuant to this
Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein
contained, the parties agree as follows:

1.   Grant of Option.The Company hereby grants to the Director, the right and
     option (the "Option") to purchase an aggregate of 1,000,000 Shares on the
     terms and  conditions of this Option at a price equal to six tenths of a
     cent ($0.006), which represents twenty  percent (20%) of the three cent
     ($.03) public bid price of Shares on the date of this Option.The exercise
     price represents the estimated fair market value of the Shares on the date
     of grant of this Option, after giving consideration to the restrictions on
     transfer and other terms and conditions of this Option.

2.   Terms of Exercise. This Option shall be exercisable as to 80,000 Shares on
     March 1, 2002 and as to an additional 80,000 Shares on the first day of
     each month thereafter until the end of February, 2003 after which date it
     shall be exercisable as to all of 1,000,000 Shares (less any for which it
     has been exercised).As an example, on and after March 1, 2002 the Director
     may exercise this Option as to 80,000 Shares; on and after April 1, 2002
     the Director may exercise this Option as to 160,000 Shares (less any Shares
     as to which the Director has already exercised this Option);and so on
     until the Director has either  exercised this Option as to all of the
     1,000,000 Shares or this Option has earlier lapsed,whichever first occurs.
     Subject to the other terms of this Agreement,as to any number of Shares
     for which this Option  may  then be exercised,this Option shall be
     exercisable at any time and from time to time in whole or in part until the
     end of the day on a date three (3) years from the date hereof, and upon the
     third anniversary of this agreement,this Option shall terminate as to any
     Shares which have not by then been purchased.

3.   Procedure.Exercise of this Option shall be by delivery or written notice
     to the Company in such form as the Company reasonably shall require at its
     principal office in St.Louis, Missouri, specifying the number of Shares
     with respect to which this Option is being exercised.Cash or a certified
     check in the amount equal to the full price of the Shares to be purchased
     shall accompany such written notice.

4.   Rights as Shareholder.The Director shall only have or exercise the rights
     of a shareholder with respect to the Shares subject to this Option after
     the Shares have been issued to him upon exercise of the Option, and not
     before its exercise.

5.   Stock Splits.In the event that prior to the purchase of the maximum number
     purchasable under this Option the Company shall have effected one or more
     reclassifications, combinations,stock dividends or split-ups of the Common
     Shares of  the Company,or other like transactions,or mergers,
     consolidations or other transactions relating to the Common Shares,the
     number of Shares thereafter purchasable under this option shall be
     adjusted, upward or downward,by the Board of Directors of the Company as
     equitable to prevent dilution or enlargement of the option right herein
     granted.In the event of an acquisition or merger in which the Company
     loses its identity,all outstanding Options shall be honored by the
     successor.

6.   Legal Requirements.The Director shall comply with all applicable laws and
     regulations regarding the purchase and sale of securities by a Director in
     a company with shares trading in a public market and shall file all
     required reports on a timely basis.

7.   Specific Performance.The parties hereto hereby agree that they will be
     irreparably damaged in the event of any controversy concerning the right or
     obligation shall be enforceable  in a court of equity by a decree or
     specific performance.Such remedy shall,however, be cumulative and
     nonexclusive,and shall be in addition to any other remedy which the
     parties may have.

8.   General.The Director understands and acknowledges that upon exercise of
     this Option,Shares purchased may not be sold, transferred, pledged or
     otherwise disposed of unless the Shares are registered under the Securities
     Act of 1933,or unless the Company has received an opinion from counsel
     satisfactory to the Company that said regulation is not required.When the
     Company becomes eligible to use federal Form s-8 for the registration of
     its Common Stock,the Company will upon request of any of the undersigned,
     register the shares purchased upon the exercise of this Option.

9.   Benefit.The Option is being issued in reliance upon an exemption from
     registration under the Securities Act of 1933 and comparable provisions of
     State statues,and may only be transferred when so registered, or in
     accordance with exemptions from such registration.This Option cannot be
     sold,transferred or otherwise disposed of by the holder hereof to any
     other person or entity unless such transaction is registered under the
     Securities Act of 1933, as amended, and under applicable laws of the state
     or jurisdiction where such transaction occurs, or unless such transaction
     shall qualify under an allowed exemption to such registration.As a
     condition to transferring this Option on the books of the Corporation, the
     holder hereof may be required to furnish the Corporation with an option of
     legal counsel satisfactory to the Corporation to the effect that the
     transaction complies with applicable securities laws.

10.  Miscellaneous.This agreement may be amended by the parties only by a
     writing signed by the party against whom enforcement is sought.This
     agreement shall insure to the benefit of and be binding upon the parties
     and their heirs and permitted successors and assigns.

IN WITNESS WHEREOF, the Company has duly executed this Agreement and the
Director has hereunto set his hand as of the day and year first below written.

GenoMed, Inc.

By: /s/Richard A. Kranitz                                    Date: 2-22-02
Richard A. Kranitz
Secretary of the Board of Directors

By: /s/David W Moskowitz
David W. Moskowitz
DirectorGenoMed, Inc. Exhibit 10.23

Exhibit 10.23

[GenoMed letterhead]

April 18, 2003

Dr. Jason Moore
Program in Human Genetics
Department of Molecular Physiology and Biophysics
519 Light Hall
Vanderbilt University Medical School
Nashville, Tennessee  37232-0700

Dear Jason,

At a special meeting of the board of directors of GenoMed, Inc. held on December
13, 2002, the board unanimously agreed to issue you nonqualified stock options
in consideration of your service to the corporation as a member of the
Scientific Advisory Board (SAB). These options are offered by the corporation as
an alternative to the outright gift of shares granted to you by your SAB
contract. Please consult with you tax attorney whether you would like to receive
the options or the gift of shares outright, and please write me by return mail
which is your choice. If I do not hear anything from you, I will assume that you
have elected to receive stock options rather than the gift of shares outright.

These stock options, in a form to be approved by the attorneys for the
corporation, are exercisable for the number of shares, and on the terms
described below:

Number of shares: one hundred thousand (100,000)

Exercise price: the closing bid price of the stock on January 16, 2003, the one
year anniversary date of the execution of your SAB contract, which was $0.012.

Time to exercise the option: 2 years from the date of issuance, i.e. until
January 16, 2005.

Please let me convey my own and the board's appreciation for your help during
this past year. (Please also forgive the tardiness of this letter.) I look
forward to working with you as our company grows.

Yours sincerely,

/s David W. Moskowitz
David W. Moskowitz
CMO, CEO, and Chairman

4560 Clayton Avenue    St. Louis, MO 63110  tel 314-977-0115  fax 314-977-0042
www.genomedics.comGenoMed, Inc. Exhibit 10.24

Exhibit 10.24

[GenoMed letterhead]

January 9, 2003

Dr. Scott Williams
Meharry Medical College
Department of Microbiology
1005 D.B. Todd Blvd.
Nashville, TN  37208

Dear Scott,

At a special meeting of the board of directors of GenoMed, Inc. held on December
13, 2002, the board unanimously agreed to issue you nonqualified stock options
in consideration of your service to the corporation as a member of the
Scientific Advisory Board (SAB), as per your contract. These stock options, in a
form to be approved by the attorneys for the corporation, are exercisable for
the number of shares, and on the price and terms described below:

Number of shares: one hundred thousand (100,000)

Exercise price:  the closing bid price of the stock on November 2, 2002, the one
year  anniversary  date of the execution of your SAB contract,  which was $0.025
(2.5 cents)

Time to exercise the option: 2 years from the date of issuance, i.e. until
November 2, 2004.

Please let me convey my own and the board's appreciation for a job well done.
(Please also forgive the tardiness of this letter.) I look forward to working
with you as our company grows.

Yours sincerely,

/s Dave Moskowitz
David W. Moskowitz
CMO, CEO, and Chairman

4560 Clayton Avenue    St. Louis, MO 63110  tel 314-977-0115  fax 314-977-0042
www.genomedics.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]